Based on the provided web search results, here’s a comprehensive reply to your query:
You mentioned tirzepatide (sold as Mounjaro and Zepbound) and its effects on weight loss. According to the trials:
- Tirzepatide helped participants lose up to 20% of their body weight over 72 weeks in a Phase III trial. It also reduced the risk of diabetes, improved heart health, mobility, and lowered blood pressure and inflammation compared to a placebo.
- In a first head-to-head clinical trial, tirzepatide (Zepbound) outperformed semaglutide (Wegovy), helping participants lose an average of 20.2% of their body weight after 72 weeks. This is about 5% more weight loss than what was achieved with semaglutide over the same period.
Additionally, you mentioned retatrutide, which is another drug developed by Eli Lilly. According to the information:
- Retatrutide, which activates receptors for GLP-1, GIP, and glucagon, has shown even more promising results than tirzepatide and semaglutide. In Phase III trials, participants lost an average of 24% of their body weight over 11 months.It also helped reduce blood-sugar levels in people with diabetes.
Here are the cited sources for the information:
anti-obesity Drug Has Life-changing Benefits for Arthritis
Researchers are excited about combination therapies such as retatrutide, says Beverly Tchang, an endocrinologist at Weill Cornell Medicine in New York City. Obesity’s complexity makes treating it challenging, but innovative approaches are emerging. For instance, orforglipron could receive US regulatory approval in 2026, according to Lilly’s chief executive Dave Ricks.
“The wild card is the oral small molecules,” says Randy Seeley, an obesity specialist at the University of Michigan medical School in Ann Arbor. Many companies are working on this approach, because pills might be more appealing and cost-effective than injections. However, progress has been slower than expected owing to dosing challenges. “If one of them finally breaks through, it has the ability to alter the landscape pretty considerably.”
MariTide: Weight-loss Maintenance
Biopharmaceutical company Amgen in Thousand Oaks, California, is planning a phase III trial of its drug candidate MariTide. This medication activates GLP-1 receptors while reducing GIP’s activity.The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company.
Unlike other treatments, MariTide has shown the ability to maintain weight loss for several months after the last dose. When people stop taking semaglutide or tirzepatide, they tend to regain weight quickly. However, that doesn’t seem to happen with MariTide, which might encourage more people to have the treatment. Seeley,who consults for and receives funding from Amgen and other companies developing obesity drugs,notes this unique benefit.
CagriSema: Combination Drug Outperforms Semaglutide
Another promising development is CagriSema,a combination drug that outperforms semaglutide. This drug combines semaglutide with setmelanotide, a medication that targets the MC4R pathway. Early trials have shown that this combination can lead to significant weight loss and improved metabolic health.
| Drug | mechanism of Action | Weight Loss percentage | Maintenance Period |
|——————–|———————————————————–|————————|——————–|
| Retatrutide | Combination therapy | Varies | Not specified |
| Orforglipron | Oral small molecule | varies | Not specified |
| MariTide | Activates GLP-1 receptors, reduces GIP activity | up to 20% | Several months |
| CagriSema | Combines semaglutide with setmelanotide | Significant | Not specified |
These advancements in obesity treatment are promising, offering new hope for individuals struggling with weight management. As research continues, the future of obesity treatment looks increasingly effective and accessible.
